Skip to main content
. 2021 Feb 1;131(3):e140315. doi: 10.1172/JCI140315

Figure 7. VLA4/VCAM1 axis mediates permeability separately from the VEGF pathway.

Figure 7

(A) TRITC-dextran permeability in HUVECs cocultured with M1 or M2 macrophages before or after treatment with bevacizumab (n = 3). (B) p–VE-cad expression in HUVECs from M1 macrophage–cocultured system or M2 macrophage–cocultured system after treated with bevacizumab (n = 3). (C) Permeability assay using M1 macrophage coculture treated with PS/2, bevacizumab, or combination of PS/2 and bevacizumab detected by the automated system (cellZscope). (D and E) Ascites volume detected by B mode ultrasonography after i.p. injection in mice with PS/2, bevacizumab, or both (n = 5). (F) Kaplan–Meier survival curves of mice after i.p. injection with PS/2, bevacizumab, or both (n = 9). (G and H) Fold change of gene expression in M1 macrophages (G) or M2 macrophages (H) treated with PS/2 compared with M1 or M2 macrophages alone (n = 3). Data represent 3 independent experiments. Results are shown as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, 1-way ANOVA (A, B, and E) and Student’s t test (G and H). The Kaplan-Meier analysis log-rank test was used to estimate the event-free survival curve between the groups (F).